We've identified the following companies as similar to CARsgen Therapeutics Holdings Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial ...

We've identified the following companies as similar to CARsgen Therapeutics Holdings Limited because they operate in a related industry or sector. We also considered size, growth, and various ...

And in November 2024, our license partner, Cutia Therapeutics, received regulatory approval to market AmZEEK in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

And in November 2024, our licensed partner, Cutia Therapeutics received regulatory approval to market Amzeeq in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

2024 reflects a $1.0 million milestone payment pursuant to Journey’s license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) that became payable to us upon Cutia receiving marketing ...

Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can ...

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...